The increasing pervasiveness of chronic diseases, to Foster the Growth of The Global Diagnostic Biomarker Market

Published: Oct 2019

The global diagnostic biomarker market is anticipated to grow at a considerable CAGR of 12.9% during the forecast period (2021-2027). The rising pervasiveness of chronic diseases is one of the prime factors affecting and driving the market. Chronic diseases include such as heart disease, cancer, diabetes, stroke, and arthritis among others that are affecting people across the globe. Rise in chronic diseases is also increasing the requirement and generating the need for research and development of diagnostic biomarker.

Browse the full report description of "Global Diagnostic Biomarker Market Research By Application (Oncology, Cardiology, Neurology, Nephrology and Other), By Diagnostic Technique (Elisa, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, and Particle-Enhanced Turbidimetric Immunoassay and Other), and By End-User (Hospitals & Diagnostic Labs and Research Centers) Forecast Period (2021-2027) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/diagnostic-biomarker-market

The key players operating in the global diagnostic biomarker market had been adopting strategy such as new launches to gain major market share. For instance, in April 2021, one of the global medical technology company Siemens Healthineers had undergone through a strategic agreement with a company providing proteomics solutions for dry discovery and development name as biognosys. With the support of this agreement both the companies would be offering customers with novel biomarkers with the means of HRM technology.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Application 

o By Diagnostic Technique 

o By End-User

    • Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

  • Competitive Landscape- Abbott, F. Hoffmann-La Roche Ltd, Merck KgaA, SIGNOSIS INC., and QIAGEN

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Diagnostic Biomarker Market - Segmentation

By Application

    • Oncology

    • Cardiology

    • Neurology

    • Nephrology

    • Other

By Diagnostic Technique

    • Elisa

    • Colorimetric Assay

    • Liquid Chromatography-Mass Spectrometry

    • Particle-Enhanced Turbidimetric Immunoassay

    • Other

By End-User

    • Hospitals & Diagnostic Labs 

    • Research Centers

Global Diagnostic Biomarker Market by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa

To learn more about this report request a sample copy @  https://www.omrglobal.com/request-sample/diagnostic-biomarker-market